MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Care Options Oncology - Colorectal Cancer' source. Wed, 17 Mar 2010 13:51:49 +0100 http://www.medworm.com/index.php?rid=3263791&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FMetastatic%2520Colorectal%2520Cancer%25202010%2FInteractive%2520Virtual%2520Presentation%2FVenook_Slides.aspx CCO Slideset - Download slides reviewing the prospect of individualized treatment in patients with colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=3263791 Thu, 11 Feb 2010 11:58:28 +0100 3263791 http://www.medworm.com/index.php?rid=3263792&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FMetastatic%2520Colorectal%2520Cancer%25202010%2FInteractive%2520Virtual%2520Presentation%2FTargeted_Agents_in_mCRC.aspx CCO Virtual Presentation - Alan P. Venook, MD, explores the future of individualized treatment in patients with colorectal cancer, with a focus on predictive biomarkers. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=3263792 Thu, 11 Feb 2010 11:50:21 +0100 3263792 http://www.medworm.com/index.php?rid=3019862&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FPractice%2520in%2520Evolution-CRC%2FVideo%2520Module%2FClinical_Insight_CRC.aspx Resource - Al B. Benson, III, MD, FACP, discusses the impact of recent data in colorectal cancer including findings from the QUASAR validation study, NSABP C-08, ACCENT, STEPP, and other phase III trials on clinical practice. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=3019862 Mon, 23 Nov 2009 12:00:00 +0100 3019862 http://www.medworm.com/index.php?rid=2990202&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FPractice%2520in%2520Evolution-CRC%2FCCO%2520Slideset%2FCRC_Slides.aspx CCO Slideset - Download slides on currently enrolling phase II/III clinical trials in colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2990202 Fri, 13 Nov 2009 10:54:12 +0100 2990202 http://www.medworm.com/index.php?rid=2986061&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FPractice%2520in%2520Evolution-CRC%2FResources%2FCALGB%252089803%2520Slides.aspx CCO Slideset - Download slides exploring the relationship between microsatellite instability and response to irinotecan, fluorouracil, and leucovorin in the adjuvant setting in stage III colon cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2986061 Thu, 12 Nov 2009 13:21:55 +0100 2986061 http://www.medworm.com/index.php?rid=2960270&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FPractice%2520in%2520Evolution-CRC%2FModule%2FCases_Cubed_CRC.aspx Discussion, Axel Grothey, MD; Cathy Eng, MD; Richard M. Goldberg, MD; and Nancy Roach explore current thinking regarding the clinical management of patients with colorectal cancer in 3 case scenarios. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2960270 Wed, 04 Nov 2009 12:00:00 +0100 2960270 http://www.medworm.com/index.php?rid=2940668&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FPractice%2520in%2520Evolution-CRC%2FResources%2FCAIRO%25202%2520Slides.aspx CCO Slideset - Download slides summarizing the CAIRO2 study of chemotherapy, bevacizumab, and cetuximab in patients with metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2940668 Thu, 15 Oct 2009 00:00:00 +0100 2940668 http://www.medworm.com/index.php?rid=2517934&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FVirtual%2520Presentation%2520Programs%2FColorectal%2520Cancer%2520ER%2FColorectal_Cancer_Slides.aspx CCO Slideset - Download slides on several of the most important data in CRC presented at the 2009 annual Clinical Oncology meeting in Orlando. Topics include new data from biomarker studies, updates in early-stage disease, new findings in locally advanced CRC, and data from studies evaluating ways to minimize treatment-related toxicity. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2517934 Tue, 23 Jun 2009 00:00:00 +0100 2517934 http://www.medworm.com/index.php?rid=2459275&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4025.aspx Capsule Summary - In a randomized, placebo-controlled phase III trial, IV CaMg protected against oxaliplatin-related chronic sensory neuropathy vs placebo in the adjuvant setting; in a separate randomized study, picoplatin was shown to be an effective alternative to oxaliplatin with less sensory neuropathy when used in combination with 5-fluorouracil and leucovorin for the first-line treatment of metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2459275 Thu, 04 Jun 2009 11:31:12 +0100 2459275 http://www.medworm.com/index.php?rid=2459276&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4000.aspx Capsule Summary - The study is the first to illustrate that a gene expression assay can be used to independently predict colon cancer recurrence risk, according to investigators. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2459276 Wed, 03 Jun 2009 14:25:30 +0100 2459276 http://www.medworm.com/index.php?rid=2459277&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4067.aspx Capsule Summary - Results from 2 phase II studies show that the combination of panitumumab and FOLFIRI is more effective in metastatic colorectal cancer patients with wild-type vs mutated KRAS. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2459277 Tue, 02 Jun 2009 20:11:27 +0100 2459277 http://www.medworm.com/index.php?rid=2459278&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4012.aspx Capsule Summary - Loss of heterozygosity at 18q was associated with significantly lower DFS and OS among patients with stage II colon cancer enrolled in the randomized CALGB 9581 trial. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2459278 Tue, 02 Jun 2009 19:05:09 +0100 2459278 http://www.medworm.com/index.php?rid=2459279&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FLung_Cancer%2FCapsules%2F8007.aspx Capsule Summary - The benefit from adding cetuximab to standard first-line chemotherapy is associated with rash and improves survival in NSCLC, regardless of KRAS mutation status or EGFR positivity. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2459279 Tue, 02 Jun 2009 13:54:00 +0100 2459279 http://www.medworm.com/index.php?rid=2459280&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4011.aspx Capsule Summary - Analysis of data from 6 recent adjuvant colon cancer trials added to the ACCENT database showed a strong concordance between both 2-year and 3-year DFS. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2459280 Tue, 02 Jun 2009 10:54:34 +0100 2459280 http://www.medworm.com/index.php?rid=2448790&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FBreast_Cancer%2FCapsules%2F502.aspx Capsule Summary - Cisplatin neoadjuvant therapy produces high pathological response rates in BRCA1-positive breast cancer patients. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2448790 Mon, 01 Jun 2009 19:50:29 +0100 2448790 http://www.medworm.com/index.php?rid=2448791&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4008.aspx Capsule Summary - Addition of oxaliplatin to standard preoperative chemoradiotherapy does not significantly improve tumor response (size, stage, or nodal involvement) in locally advanced rectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2448791 Sun, 31 May 2009 20:22:39 +0100 2448791 http://www.medworm.com/index.php?rid=2448792&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4007.aspx Capsule Summary - The addition of oxaliplatin to preoperative chemoradiotherapy had no significant effect on tumor response or outcomes in patients with locally advanced, stage T3-4 rectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2448792 Sun, 31 May 2009 20:07:53 +0100 2448792 http://www.medworm.com/index.php?rid=2448793&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FBreast_Cancer%2FCapsules%2F512.aspx Capsule Summary - The addition of adjuvant chemotherapy to hormonal therapy benefits breast cancer patients classified as high risk. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2448793 Sun, 31 May 2009 17:21:57 +0100 2448793 http://www.medworm.com/index.php?rid=2517937&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4001.aspx Capsule Summary - Analyses of a major European study revealed that microsatellite instability was one strong prognostic factor for RFS and OS in stage II colon cancer. Results of further analysis showing the stage-specific prognostic value of various markers led investigators to consider that disease “stages” may actually represent distinct diseases, rather than an evolution of a single disease. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2517937 Fri, 29 May 2009 00:00:00 +0100 2517937 http://www.medworm.com/index.php?rid=2517936&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2FLBA4.aspx Capsule Summary - The addition of bevacizumab to oxaliplatin-based chemotherapy does not significantly prolong DFS in patients with stage II/III colon cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2517936 Fri, 29 May 2009 00:00:00 +0100 2517936 http://www.medworm.com/index.php?rid=2517935&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FCapsules%2F4016.aspx Capsule Summary - Combined wild-type KRAS status and high EREG expression was identified as predictive of cetuximab benefit; in a separate study, both KRAS and BRAF mutation were shown to be strong negative predictors of cetuximab or panitumumab efficacy. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2517935 Fri, 29 May 2009 00:00:00 +0100 2517935 http://www.medworm.com/index.php?rid=2635578&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FColorectal_Cancer%2FColorectal_Cancer.aspx Learning Module - Edward Chu, MD; Richard Goldberg, MD; and Alan Venook, MD, discuss the clinical implications of the most recent data in colorectal cancer, including the prognostic and predicative value of molecular biomarkers, the role of VEGF inhibitors, the correlation of disease-free survival and overall survival, and the impact of older age on the efficacy of newer adjuvant therapies in stage II and III disease. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2635578 Wed, 11 Mar 2009 00:00:00 +0100 2635578 http://www.medworm.com/index.php?rid=2664880&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FVirtual%2520Presentation%2520Programs%2FColorectal%2520Cancer%2520ER%2FColorectal_Cancer.aspx CCO Expert Recap - Alan P. Venook, MD, explores the most compelling data in colorectal cancer presented at the 2009 Clinical Oncology meeting. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2664880 Wed, 07 Jan 2009 00:00:00 +0100 2664880 http://www.medworm.com/index.php?rid=1954599&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2FLBA4011.aspx In patients with advanced colorectal cancer and KRAS mutation, adding cetuximab to capecitabine, oxaliplatin, and bevacizumab is associated with a significant shortening of PFS (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1954599 Thu, 13 Nov 2008 09:37:54 +0100 1954599 http://www.medworm.com/index.php?rid=1917379&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2F4010.aspx Final results from the phase III CONcePT trial demonstrate that intermittent oxaliplatin compared with continuous treatment increases time to treatment failure in patients with mCRC. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1917379 Thu, 30 Oct 2008 08:43:39 +0100 1917379 http://www.medworm.com/index.php?rid=1899896&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2F4009.aspx Despite early termination based on negative results from a different study, a randomized, controlled trial demonstrated that IV calcium and magnesium reduced neurotoxicity in patients with stage II/III colon cancer receiving adjuvant FOLFOX (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1899896 Fri, 24 Oct 2008 09:17:06 +0100 1899896 http://www.medworm.com/index.php?rid=1814684&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2F4008.aspx In stage II/III chemotherapy-naive colon cancer patients, deficient mismatch repair predicts lack of benefit from 5-FU-based chemotherapy (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1814684 Tue, 23 Sep 2008 09:08:55 +0100 1814684 http://www.medworm.com/index.php?rid=1805447&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2F4006.aspx In initial safety analysis from NSABP C-08, bevacizumab added to mFOLFOX6 appears well tolerated in the adjuvant setting for patients with stage II or III advanced colorectal cancer with no compromise in FOLFOX6 dose intensity (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1805447 Fri, 19 Sep 2008 08:46:16 +0100 1805447 http://www.medworm.com/index.php?rid=1732961&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2FLBA4005.aspx Latest data from large phase III trial in patients with stage II/III colon cancer suggest improved OS at 5 years-and confirm superior PFS-for oxaliplatin added to 5-FU/LV in adjuvant therapy (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1732961 Wed, 27 Aug 2008 07:50:58 +0100 1732961 http://www.medworm.com/index.php?rid=1699652&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2F4004.aspx Addition of FDG-PET to CT scan results in decreased number of unnecessary laparotomies in patients with colorectal liver metastases (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1699652 Wed, 13 Aug 2008 07:57:05 +0100 1699652 http://www.medworm.com/index.php?rid=2517938&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FVirtual%2520Presentation%2520Programs%2FGI%2520Cancer%2520ER%2FGastrointestinal%2520Cancers.aspx CCO Expert Recap - John L. Marshall, MD, discusses highlights from several of the key studies presented at the 2008 Annual Meeting of the American Society of Clinical Oncology, including advances in the role of biomarkers in gastrointestinal cancer treatment efficacy. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2517938 Thu, 31 Jul 2008 00:00:00 +0100 2517938 http://www.medworm.com/index.php?rid=1654708&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2F4001.aspx Cetuximab, in standard or escalating doses, combined with irinotecan induces responses in mCRC patients in whom the chemotherapeutic agent previously failed, but only in those with wild-type KRAS (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1654708 Sat, 26 Jul 2008 07:29:50 +0100 1654708 http://www.medworm.com/index.php?rid=2517939&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FGastrointestinal%2520Cancers.aspx Learning Module - Axel Grothey, MD, John L. Marshall, MD, and Richard M. Goldberg, MD, examine new data on biomarkers and response to biologic and chemotherapeutic agents in colorectal cancer, combination adjuvant treatment regimens in colorectal cancer, chemotherapy in advanced pancreatic cancer, and other topics—and discuss implications for clinical practice. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2517939 Fri, 25 Jul 2008 00:00:00 +0100 2517939 http://www.medworm.com/index.php?rid=2517940&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FCancer%2520Research%25202008%2FTracks%2FCancer%2520Research%2FCancer%2520Research.aspx Learning Module - Roy S. Herbst, MD, PhD, and Andrew X. Zhu, MD, PhD, discuss recent clinical trial data and novel targets presented at the 2008 American Assciation for Cancer Research meeting. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2517940 Thu, 26 Jun 2008 00:00:00 +0100 2517940 http://www.medworm.com/index.php?rid=1541296&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2F4000.aspx Adding cetuximab to FOLFOX benefits metastatic colorectal cancer patients with wild-type KRAS tumors, but not those with mutant KRAS (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1541296 Wed, 25 Jun 2008 20:44:42 +0100 1541296 http://www.medworm.com/index.php?rid=1517838&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FGastrointestinal%2FCapsules%2F2.aspx Retrospective efficacy analysis of CRYSTAL trial reveals that addition of cetuximab to FOLFIRI appears to only benefit metastatic colorectal cancer patients with wild-type KRAS (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1517838 Sat, 14 Jun 2008 20:50:43 +0100 1517838 http://www.medworm.com/index.php?rid=2517941&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FTargeted%2520Therapies%2FCCO%2520Slidesets%2FEGFR%2520Slides.aspx CCO Slideset - David Cunningham, MD, FRCP discusses the rationale for targeting the EGFR with monoclonal antibodies and gives an update on their use in gastrointestinal cancers as monotherapy and in combination with chemotherapies. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=2517941 Thu, 12 Jun 2008 00:00:00 +0100 2517941 http://www.medworm.com/index.php?rid=1395896&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FLiver%2520Metastases%2520Master%2520Class%2FVirtual%2520Presentation%2FMaster%2520Class%2520Virtual%2520Presentation.aspx Steven R. Alberts, MD, reviews recent data on current and novel therapeutic approaches for managing liver metastases in patients with colorectal cancer and examines how this knowledge is applied in practice in 3 patient cases. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1395896 Thu, 24 Apr 2008 19:45:29 +0100 1395896 http://www.medworm.com/index.php?rid=1367454&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FGI%25202008%2FTracks%2FColorectal%2520Cancers%2FColorectal%2520Cancers.aspx Alan P. Venook, MD, and Richard M. Goldberg, MD, discuss results presented at the 2008 Gastrointestinal Cancers Symposium regarding current therapy for colorectal cancers. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1367454 Sat, 12 Apr 2008 07:23:56 +0100 1367454 http://www.medworm.com/index.php?rid=1364475&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FmCRC%2520Advances%2FVirtual%2520Presentations%2FVan%2520Cutsem.aspx Eric Van Cutsem, MD, PhD, discusses the emerging use of biomarkers in the clinical management of patients with metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1364475 Fri, 11 Apr 2008 07:11:24 +0100 1364475 http://www.medworm.com/index.php?rid=1312229&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FmCRC%2520Advances%2FVirtual%2520Presentations%2FEng.aspx Cathy Eng, MD, reviews recent data regarding the use of clinical data to optimize treatment of colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1312229 Wed, 19 Mar 2008 07:30:29 +0100 1312229 http://www.medworm.com/index.php?rid=1302823&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FmCRC%2520Advances%2FVirtual%2520Presentations%2FChu.aspx Edward Chu, MD, reviews neoadjuvant strategies to improve outcomes in patients with liver-limited metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1302823 Fri, 14 Mar 2008 19:20:24 +0100 1302823 http://www.medworm.com/index.php?rid=1298541&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FmCRC%2520Advances%2FVirtual%2520Presentations%2FHecht.aspx J. Randolph Hecht, MD, reviews current therapeutic options for metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1298541 Thu, 13 Mar 2008 07:23:23 +0100 1298541 http://www.medworm.com/index.php?rid=1020845&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FCRC%2520-%2520Oral%2520Therapy%2FModules%2FTreatment%2520Update.aspx David H. Ilson, MD, PhD, describes recent data on treatment approaches using oral agents in the management of colon and rectal cancers. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1020845 Tue, 13 Nov 2007 01:13:10 +0100 1020845 http://www.medworm.com/index.php?rid=1010185&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FCRC%2520-%2520Oral%2520Therapy%2FInteractive%2520Case%2520Challenges%2FMetastatic%2520Colorectal.aspx Alan P. Venook, MD reviews options for cytotoxic and targeted agents as first-line treatment of a patient with metastatic colorectal cancer and Gilberts syndrome. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=1010185 Wed, 07 Nov 2007 13:25:59 +0100 1010185 http://www.medworm.com/index.php?rid=988095&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FManagement%2520Series%2FGI%2520Cancer%2FModules%2FNovel.aspx Daniel G. Haller, MD, reviews the current treatment of advanced colorectal cancer and discusses emerging therapies. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=988095 Tue, 30 Oct 2007 00:05:54 +0100 988095 http://www.medworm.com/index.php?rid=920843&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FManagement%2520Series%2FGI%2520Cancer%2FModules%2FDetection.aspx Heinz-Josef Lenz, MD, reviews modalities for the detection and imaging of colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=920843 Wed, 03 Oct 2007 00:01:59 +0100 920843 http://www.medworm.com/index.php?rid=887430&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FManagement%2520Series%2FGI%2520Cancer%2FModules%2FColon.aspx Richard M. Goldberg, MD, reviews the current use of adjuvant chemotherapy for patients with colon cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=887430 Fri, 21 Sep 2007 00:08:25 +0100 887430 http://www.medworm.com/index.php?rid=869037&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FManagement%2520Series%2FGI%2520Cancer%2FModules%2FPrevention.aspx Axel Grothey, MD, reviews strategies to decrease the risk of colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=869037 Fri, 14 Sep 2007 00:54:20 +0100 869037 http://www.medworm.com/index.php?rid=857721&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FManagement%2520Series%2FGI%2520Cancer%2FModules%2FRectal.aspx Joel E. Tepper, MD, reviews the current use of adjuvant chemotherapy for patients with rectal cancer (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=857721 Tue, 11 Sep 2007 00:38:49 +0100 857721 http://www.medworm.com/index.php?rid=846971&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FManagement%2520Series%2FGI%2520Cancer%2FModules%2FScreening.aspx Dennis J. Ahnen, MD, reviews current and emerging screening techniques for colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=846971 Fri, 07 Sep 2007 00:26:57 +0100 846971 http://www.medworm.com/index.php?rid=782511&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FGastrointestinal%2520Cancer.aspx Axel Grothey, MD, John L. Marshall, MD, and Alan P. Venook, MD, review data from the meeting in Chicago. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=782511 Tue, 07 Aug 2007 00:10:09 +0100 782511 http://www.medworm.com/index.php?rid=751196&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4021.aspx Results of a retrospective analysis of biomarkers in metastatic colorectal cancer suggested that a combination of EGFR copy number and K-ras mutational status may improve prediction of response to cetuximab therapy. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=751196 Tue, 24 Jul 2007 00:16:06 +0100 751196 http://www.medworm.com/index.php?rid=746440&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4003.aspx Results of the phase III EPIC trial demonstrate improvements in quality of life when cetuximab is added to irinotecan in patients with metastatic colorectal cancer who previously failed treatment with oxaliplatin-based therapy. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=746440 Sat, 21 Jul 2007 00:24:03 +0100 746440 http://www.medworm.com/index.php?rid=737196&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4000.aspx Results of the phase III CRYSTAL trial show that first-line combination treatment with cetuximab and FOLFIRI is well tolerated and significantly improved clinical outcomes vs FOLFIRI alone in patients with metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=737196 Tue, 17 Jul 2007 00:49:43 +0100 737196 http://www.medworm.com/index.php?rid=737195&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2FLBA1.aspx In a phase III trial, sorafenib was associated with a 44% increase in overall survival and a 73% increase in time to progression for patients with advanced HCC. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=737195 Tue, 17 Jul 2007 00:49:43 +0100 737195 http://www.medworm.com/index.php?rid=729389&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4513.aspx S-1 was shown to be noninferior to 5-FU in a phase III study of patients with unresectable or recurrent gastric cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=729389 Thu, 12 Jul 2007 16:57:10 +0100 729389 http://www.medworm.com/index.php?rid=729388&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4007.aspx In final 6-year follow-up, FOLFOX4 improved disease-free and overall survival for patients with stage III colon cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=729388 Thu, 12 Jul 2007 16:57:10 +0100 729388 http://www.medworm.com/index.php?rid=715811&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2FLBA5.aspx Results of the EORTC 40983 phase III study show that perioperative FOLFOX4 therapy improved PFS in patients with colorectal cancer with resectable liver metastases compared with surgery alone. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=715811 Fri, 06 Jul 2007 06:36:10 +0100 715811 http://www.medworm.com/index.php?rid=705288&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4010.aspx Results of a multicenter international study show that circulating tumor cells are a significant independent positive prognostic factor for survival in patients with metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=705288 Sat, 30 Jun 2007 02:49:11 +0100 705288 http://www.medworm.com/index.php?rid=705287&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4036.aspx In an exploratory analysis of the BRiTE registry, patients with metastatic colorectal cancer treated with bevacizumab beyond first progression appear to have longer overall and median survival compared with patients who do not receive postprogression bevacizumab. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=705287 Sat, 30 Jun 2007 02:49:11 +0100 705287 http://www.medworm.com/index.php?rid=697890&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4028.aspx Addition of bevacizumab to oxaliplatin-based chemotherapy prolonged progression-free survival and showed a trend toward improved overall survival in patients with previously untreated metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=697890 Wed, 27 Jun 2007 03:27:22 +0100 697890 http://www.medworm.com/index.php?rid=697889&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4027.aspx Updated BICC-C results demonstrate that FOLFIRI without bevacizumab produced significantly better progression-free survival than modified-bolus IFL or CapeIri and better overall survival than modified-bolus IFL when combined with bevacizumab in metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=697889 Wed, 27 Jun 2007 03:27:22 +0100 697889 http://www.medworm.com/index.php?rid=680485&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4019.aspx In a prospective, observational study of patients treatmed for stage III colon cancer, a "Western" diet is associated with worse progression-free, recurrence-free, and overall survival compared with a more "prudent" diet (eg, high intake of fruit, vegetables, poultry, and fish). (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=680485 Wed, 20 Jun 2007 19:55:01 +0100 680485 http://www.medworm.com/index.php?rid=680484&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4006.aspx A retrospective analysis of INT 0114 shows lymph node ratio (proportion of positive to total examined) predicts survival in patients with resected node-positive rectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=680484 Wed, 20 Jun 2007 19:55:01 +0100 680484 http://www.medworm.com/index.php?rid=668413&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4516.aspx In preliminary results of a multicenter, randomized, phase II study comparing the FOLFIRINOX regimen with standard gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma, FOLFIRINOX was generally well tolerated and associated with a response rate greater than 30%. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=668413 Sun, 17 Jun 2007 00:48:55 +0100 668413 http://www.medworm.com/index.php?rid=668412&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4514.aspx Results of the phase III SPIRITS trial show that in patients with advanced gastric cancer, first-line treatment with the oral fluoropyrimidine S-1 in combination with cisplatin confers significantly higher rates of tumor response and survival compared with S-1 monotherapy. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=668412 Sun, 17 Jun 2007 00:48:55 +0100 668412 http://www.medworm.com/index.php?rid=668411&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2FLBA4509.aspx In the SWOG S0205 phase III trial, gemcitabine plus cetuximab did not increase response or survival vs gemcitabine monotherapy in patients with advanced-stage pancreatic cancer (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=668411 Sun, 17 Jun 2007 00:48:55 +0100 668411 http://www.medworm.com/index.php?rid=668410&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4510.aspx Results of the randomized ACCORD 07 trial show that, compared with surgery alone, preoperative 5-FU plus cisplatin offers significant improvements in rates of curative resection, OS, and DFS, with no increase in morbidity (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=668410 Sun, 17 Jun 2007 00:48:55 +0100 668410 http://www.medworm.com/index.php?rid=668409&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4012.aspx Median overall survival was not prolonged with the combined use of cytotoxic drugs (capecitabine, irinotecan, oxaliplatin) compared with sequential therapy in patients with advanced colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=668409 Sun, 17 Jun 2007 00:48:55 +0100 668409 http://www.medworm.com/index.php?rid=668408&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4508.aspx Results of the phase III CALGB 80303 study of patients with advanced pancreatic cancer showed bevacizumab plus gemcitabine increased the rate of hypertension and proteinuria and did not significantly improve survival or response vs gemcitabine plus placebo (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=668408 Sun, 17 Jun 2007 00:48:55 +0100 668408 http://www.medworm.com/index.php?rid=668407&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202007%2FTracks%2FGastrointestinal%2520Cancer%2FCapsules%2F4013.aspx Final results of OPTIMOX2 phase II study do not support the introduction of a chemotherapy-free interval (CFI) following FOLFOX7 chemotherapy in patients with metastatic colorectal cancer (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=668407 Sun, 17 Jun 2007 00:48:55 +0100 668407 http://www.medworm.com/index.php?rid=607622&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FGI%25202007%2FTracks%2FColorectal%2520Cancer%2FColorectal.aspx Richard M. Goldberg, MD, and John L. Marshall, MD, report from the gastrointestinal cancers meeting in Orlando. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=607622 Thu, 17 May 2007 23:05:16 +0100 607622 http://www.medworm.com/index.php?rid=607621&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FGI%25202007%2FTracks%2FPancreatic%2C%2520Small%2520Bowel%2C%2520and%2520Hepatobiliary%2520Cancers%2FPancreatic.aspx Barbara Burtness, MD, and Eric Van Cutsem, MD, PhD, report from the gastrointestinal cancers meeting in Orlando. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=607621 Thu, 17 May 2007 23:05:16 +0100 607621 http://www.medworm.com/index.php?rid=607620&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FGI%25202007%2FTracks%2FStomach%2520and%2520Esophageal%2520Cancers%2FStomach.aspx David H. Ilson, MD, PhD, and Joel E. Tepper, MD, report from the gastrointestinal cancers meeting in Orlando. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=607620 Thu, 17 May 2007 23:05:16 +0100 607620 http://www.medworm.com/index.php?rid=375397&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FCRC%2FModules%2FBiology.aspx Review the biology of colorectal cancer in this treatment update, which includes discussions of molecular targets in advanced disease and recent clinical trials of targeted agents in combination with chemotherapy. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=375397 Tue, 23 Jan 2007 12:50:02 +0100 375397 http://www.medworm.com/index.php?rid=315054&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FCRC%2FModules%2FCRC%2520Mgmt.aspx Peruse this treatment update for the most recent data on the management of metastatic colorectal cancer, including a review of continuous vs intermittent chemotherapy, and the integration of targeted agents into standard treatment practices. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=315054 Tue, 12 Dec 2006 09:32:01 +0100 315054 http://www.medworm.com/index.php?rid=237162&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FTracks%2FGastrointestinal%2520%28Non-Colorectal%29%2FGastrointestinal%2520%28Non-Colorectal%29%2520Cancer.aspx Jaffer A. Ajani, MD, David H. Ilson, MD, PhD, and Anthony El-Khoueiry, MD, review data from recent studies regarding emerging treatment regimens for esophagogastric cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=237162 Tue, 17 Oct 2006 08:50:01 +0100 237162 http://www.medworm.com/index.php?rid=221475&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FTracks%2FGastrointestinal%2520%28Colorectal%29%2FGastrointestinal%2520%28Colorectal%29%2520Cancer.aspx CCO Oncology - Edward Chu, MD, John L. Marshall, MD, and Alan P. Venook, MD, review data from recent studies regarding the treatment of colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=221475 Thu, 05 Oct 2006 11:00:01 +0100 221475 http://www.medworm.com/index.php?rid=178479&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FCase%2520Challenges%2FColorectal%2520Cancer%2FInteractive%2520Case%2520Challenges%2FMarshall.aspx Investigate the adjuvant treatment of colorectal cancer including the role of oral fluoropyrimidines, the use of combination therapies, and the implications of data from recent clinical trials. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=178479 Thu, 07 Sep 2006 23:33:02 +0100 178479 http://www.medworm.com/index.php?rid=162088&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FVirtual%2520Presentation%2520Programs%2FColorectal.aspx Along with John L. Marshall, MD, investigate data presented at the recent annual meeting of the American Society of Clinical Oncology, including studies of intermittent chemotherapy, novel combination regimens, and gene expression in colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=162088 Wed, 30 Aug 2006 05:42:01 +0100 162088 http://www.medworm.com/index.php?rid=155025&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FCase%2520Challenges%2FColorectal%2520Cancer%2FInteractive%2520Case%2520Challenges%2FChu.aspx Study the treatment of a patient with metastatic colorectal cancer, the choice of treatment regimen and appropriate surgical approaches to therapy. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=155025 Thu, 24 Aug 2006 05:47:02 +0100 155025 http://www.medworm.com/index.php?rid=126867&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3518.aspx%3FTrack%3DGastrointestinal+%28Colorectal%29 CCO Oncology - Analysis of tissue samples revealed 78 genes with prognostic significance, while preliminary results of a follow-up analysis confirmed the prognostic significance of many genes. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=126867 Sun, 30 Jul 2006 23:03:02 +0100 126867 http://www.medworm.com/index.php?rid=126866&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2FLBA4018.aspx%3FTrack%3DGastrointestinal+%28Non-Colorectal%29 CCO Oncology - In a phase III trial, capecitabine plus cisplatin was not inferior to standard 5-fluorouracil/cisplatin in patients with advanced gastric cancer. The two treatment regimens had similar toxicity profiles. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=126866 Sun, 30 Jul 2006 23:03:02 +0100 126866 http://www.medworm.com/index.php?rid=109809&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2FLBA4017.aspx%3FTrack%3DGastrointestinal+%28Non-Colorectal%29 CCO Oncology - In a phase III study, capecitabine and oxaliplatin were shown to be acceptable substitutes for 5-fluorouracil and cisplatin in epirubicin-based triplet therapy for advanced esophagogastric carcinoma. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=109809 Wed, 19 Jul 2006 00:10:27 +0100 109809 http://www.medworm.com/index.php?rid=102755&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3521.aspx%3FTrack%3DGastrointestinal+%28Colorectal%29 CCO Oncology - Analysis of initial data from the Internet-based LiveretSurvey registry have confirmed that intrahepatic tumor burden is an important prognostic variable in patients with colorectal liver metastases. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=102755 Sat, 15 Jul 2006 06:00:00 +0100 102755 http://www.medworm.com/index.php?rid=102754&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3519.aspx%3FTrack%3DGastrointestinal+%28Colorectal%29 CCO Oncology - A 42-gene signature derived from a colon cancer-specific array accurately predicted risk of relapse using tissue samples from patients with stage II colorectal cancer, investigators reported at the 42nd Annual Meeting of the American Society of Clinical Oncology in Atlanta, Georgia. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=102754 Sat, 15 Jul 2006 06:00:00 +0100 102754 http://www.medworm.com/index.php?rid=89310&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3517.aspx%3FTrack%3DGastrointestinal+%28Colorectal%29 CCO Oncology - Results of a retrospective analysis of 4 clinical trials indicates that age alone does not predict for increase in toxicity to FOLFOX4 in the treatment of colorectal cancer. The findings suggest patients should not be excluded from chemotherapy for colorectal cancer on the basis of age alone. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=89310 Thu, 06 Jul 2006 06:00:00 +0100 89310 http://www.medworm.com/index.php?rid=83094&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3513.aspx%3FTrack%3DGastrointestinal+%28Colorectal%29 CCO Oncology - In a phase III study, the response rate and time to disease progression for FOLFOXIRI was superior to FOLFIRI as first-line therapy for patients with metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=83094 Fri, 30 Jun 2006 06:00:00 +0100 83094 http://www.medworm.com/index.php?rid=83093&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3510.aspx%3FTrack%3DGastrointestinal+%28Colorectal%29 CCO Oncology - In the TREE-2 clinical trial of patients with untreated metastatic colorectal cancer, the addition of bevacizumab to oxaliplatin/fluoropyrimidine regimens significantly improved overall survival and time to progression but did not improve time to treatment failure. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=83093 Fri, 30 Jun 2006 06:00:00 +0100 83093 http://www.medworm.com/index.php?rid=73692&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2FLBA4004.aspx%3FTrack%3DGastrointestinal CCO Oncology - In a phase III trial of patients with advanced pancreatic cancer, neither fixed-doserate gemcitabine nor gemcitabine combined with oxaliplatin demonstrated statistically significant survival or response rate improvements in patients with advanced pancreatic cancer vs gemcitabine monotherapy. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=73692 Fri, 23 Jun 2006 06:00:00 +0100 73692 http://www.medworm.com/index.php?rid=67066&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F4024.aspx%3FTrack%3DGastrointestinal CCO Oncology - Complete response was not predicted by negative endoscopic biopsy, leading investigators to state that surgical resection after chemoradiation remains optimal method of assessing response to treatment. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=67066 Tue, 20 Jun 2006 06:00:00 +0100 67066 http://www.medworm.com/index.php?rid=67065&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F4009.aspx%3FTrack%3DGastrointestinal CCO Oncology - According to results of a multicenter phase III study, the combination of cisplatin, 5-FU, and radiation is not superior to mitomycin-C, 5-FU, and radiation in the treatment of anal carcinoma. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=67065 Tue, 20 Jun 2006 06:00:00 +0100 67065 http://www.medworm.com/index.php?rid=61083&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3519.aspx%3FTrack%3DGastrointestinal CCO Oncology - A 42-gene signature derived from a colon cancerspecific array accurately predicted risk of relapse using tissue samples from patients with stage II colorectal cancer, investigators reported at the 42nd Annual Meeting of the American Society of Clinical Oncology in Atlanta, Georgia. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=61083 Wed, 14 Jun 2006 06:00:00 +0100 61083 http://www.medworm.com/index.php?rid=59468&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FResources%2FNews%2520and%2520Comment%2FExpert%2520Viewpoints%2FApril%25202006.aspx CCO Oncology - In April 2006, provocative new data were discussed at the plenary session entitled, "Breakthroughs in Clinical Research," held during the 97th Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC. Presented abstracts focused on breakthroughs in 2 areas: colorectal cancer (CRC) and chronic myeloid leukemia (CML). This commentary reviews and discusses the clinical implications of the evidence presented. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=59468 Tue, 13 Jun 2006 06:00:00 +0100 59468 http://www.medworm.com/index.php?rid=59467&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FResources%2FNews%2520and%2520Comment%2FArticles%2Fnews_imed_168.aspx CCO Oncology - Chemotherapy delivered through hepatic arterial infusion (HAI) improved overall survival, response rate, and time to hepatic progression (THP) in colorectal cancer patients with unresectable liver metastases, according to a study recently published in the Journal of Clinical Oncology. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=59467 Tue, 13 Jun 2006 06:00:00 +0100 59467 http://www.medworm.com/index.php?rid=59466&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FNews%2FNews_9513.aspx CCO Oncology - Sunitinib significantly prolongs time to progression (TTP) in patients with gastrointestinal stromal tumors (GIST) following imatinib failure due to resistance or intolerance, according to updated results of a double-blind, placebo-controlled phase III trial presented by Paolo Casali, MD, from the Instituto Nazionale Tumori in Milan, Italy, at the 42nd Annual Meeting of the American Society for Clinical Oncology in Atlanta, Georgia. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=59466 Tue, 13 Jun 2006 06:00:00 +0100 59466 http://www.medworm.com/index.php?rid=59465&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3518.aspx%3FTrack%3DGastrointestinal CCO Oncology - Analysis of tissue samples revealed 78 genes with prognostic significance, while preliminary results of a follow-up analysis confirmed the prognostic significance of many genes. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=59465 Tue, 13 Jun 2006 06:00:00 +0100 59465 http://www.medworm.com/index.php?rid=59464&cid=s_31087_6_f&fid=31087&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Oncology%2520June%25202006%2FCapsules%2F3503.aspx%3FTrack%3DGastrointestinal CCO Oncology - Genetic factors may explain racial differences in outcome and toxicity for patients treated with platinum-based regimens for metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer) Clinical Care Options Oncology - Colorectal Cancer journals http://www.medworm.com/rss/comments.php?id=59464 Tue, 13 Jun 2006 06:00:00 +0100 59464